Tappeiner, Christoph; Möller, Burkhard; Hennig, Maren; Heiligenhaus, Arnd (2012). New biologic drugs: anti-interleukin therapy. In: Foster, C S; Miserocchi, E; Modorati, G (eds.) New Treatments in Noninfectious Uveiti. Developments in Ophthalmology: Vol. 51 (pp. 79-89). Basel: Karger 10.1159/000336190
Full text not available from this repository.nterleukins (ILs) are cytokines which are defined by their capability to convey information between leukocytes, in this way directing proliferation, activation, and migration and also regulation of the cells. Data from anti-IL treatments in systemic autoimmune diseases have shown these drugs to be beneficial and to have a satisfactory safety profile and tolerance. Recent publications of small case series suggest that several anti-IL drugs have considerable efficacy in treating otherwise refractory uveitis. Anti-IL therapy, therefore, might constitute an option for the treatment of uveitis resistant to corticosteroids, classical immunosuppressives, or tumor necrosis factor-α inhibitors. However, due to high costs and possible long-term risks, anti-IL agents should currently be reserved to selected uveitis patients and be administered only under close interdisciplinary monitorin
Item Type: |
Book Section (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology 04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology and Immunology |
UniBE Contributor: |
Tappeiner, Christoph, Möller, Burkhard |
ISSN: |
0250-3751 |
ISBN: |
978-3-8055-9987-0 |
Series: |
Developments in Ophthalmology |
Publisher: |
Karger |
Language: |
English |
Submitter: |
Christoph Tappeiner |
Date Deposited: |
04 Oct 2013 14:23 |
Last Modified: |
05 Dec 2022 14:06 |
Publisher DOI: |
10.1159/000336190 |
PubMed ID: |
22517206 |
URI: |
https://boris.unibe.ch/id/eprint/8119 (FactScience: 213604) |
Actions (login required)
 |
Edit item |